Halozyme Therapeutics Inc (HALO)

[biotech2020]

Thanks for the correction. I agree that Fezziwig2008 may overdo his promotion of Halo on Twitter, but he seems knowledgeable about the science and usually provides good information. I had a decent size Halo position last year, but it was called away at 15, which I regretted at the time after it climbed higher. As with a lot of biotechs this year, the price dropped well below what I consider a reasonable valuation, and I rebuilt a much larger Halo position than I've ever had. Without the PEGPH20 trials, Halo would be earning over a $1.00 per share giving them a PE under 10, with the low risk, high growth Enhaze platform. IMO, the PEGPH20 is essentially a free option that offers considerable upside but little downside risk at current PPS.